Candidiasis, commonly caused by the yeast Candida albicans, is an opportunistic oral or genital infection that affects people with weakened immune systems. Symptoms include vaginal itching and discharge, as well as oral thrush. The global candidiasis market has seen considerable growth in recent years driven by the development of accurate diagnostics and innovative anti-fungal therapeutics. Conventionally, candidiasis was diagnosed based on clinical signs and symptoms or smear microscopy. However, newer molecular and biochemical diagnostic techniques have enabled rapid and definitive identification of Candida species, allowing timely treatment. Moreover, the market has witnessed the approval of novel drugs such as Echinocandins with distinct mechanisms of action and improved safety profiles.
The global candidiasis market size was valued at US$ 873.8 million in 2017, and is expected to exhibit a CAGR of 4.6% over the forecast period (2018–2026).
Key Takeaways
Key players operating in the Candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others. These players are focused on ramping up research and development activities to expand their product portfolios.
The Candidiasis Market Demand provides lucrative opportunities for new players to foray into drug development for candidiasis. Unmet needs like antifungal resistance and limited treatment options for invasive Candida infections present key focus areas.
Advancements in molecular diagnostics allow for rapid identification of Candida species, adjudging antifungal susceptibility, and detecting drug resistance. This aids effective management of fungal infections through early diagnosis and targeted treatment.
Market drivers
Rising prevalence of HIV/AIDS and nosocomial candidal infections: The growing HIV/AIDS patient pool and increasing incidence of hospital-acquired Candida infections are major factors driving the need for improved diagnostic tools and anti-fungal therapies.
Increasing focus on RD: Significant investments by major pharmaceutical companies in research and clinical trials for novel drug classes like orotomides, SCY-078, and APX001 are expected to help address the unmet needs in candidiasis treatment.
Get More Insights on- Candidiasis Market
Explore More Related Article On- Sterile Injectables Market
For Deeper Insights, Find the Report in the Language that You want:
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
